Optimizing Cell Viability and Nuclear Visualization with DAP
2026-07-31
This article provides an evidence-based roadmap for using DAPI Solution (1 mg/mL) (SKU K2401) in cell viability, apoptosis, and nuclear visualization workflows. Through scenario-driven Q&A, it addresses real laboratory challenges and benchmarks APExBIO's DAPI against practical needs for reproducibility, sensitivity, and workflow efficiency.
Small Molecule Inhibition of uPAR·uPA Disrupts Cancer Invasi
2026-07-31
Khanna et al. introduce IPR-456, the first small molecule inhibitor to disrupt the tight urokinase receptor (uPAR) and urokinase-type plasminogen activator (uPA) interaction, critical to metastatic signaling in cancer. By targeting multiple protein conformations, their approach demonstrates that rationally designed molecules can block cell invasion, providing a new avenue for anti-metastatic therapy and mechanistic study.
Verteporfin Beyond PDT: Mechanistic Insights and Assay Desig
2026-07-30
Explore Verteporfin’s dual role in photodynamic therapy and autophagy inhibition, with a focus on advanced assay strategies and the latest regulatory network insights. This article reveals how Verteporfin empowers research in ocular neovascularization and lineage commitment, offering guidance distinct from conventional protocols.
2-D08: Precision SUMOylation Inhibition in Cancer Cell Studi
2026-07-30
2-D08 (2’,3’,4’-trihydroxyflavone) offers researchers unique, selective inhibition of protein sumoylation, enabling clear dissection of posttranslational pathways in cancer and mitochondrial biology. Its high specificity and robust solubility profile make it an advanced tool for quantifying SUMO-dependent modifications and optimizing cellular models for disease research.
Sabutoclax: Pan-Bcl-2 Inhibitor Streamlining Cancer Assays
2026-07-29
Sabutoclax stands out as a potent pan-Bcl-2 inhibitor, offering robust, reproducible apoptosis induction in both in vitro and in vivo cancer models. Its high selectivity and superior membrane permeability make it indispensable for researchers aiming for precise, high-fidelity drug response profiling in apoptosis-focused workflows.
Ertugliflozin Modulates Brain Insulin Signaling in Alzheimer
2026-07-29
This study demonstrates that Ertugliflozin (PF-04971729), a selective SGLT2 inhibitor, reverses cognitive deficits and tau hyperphosphorylation in a rat model of Alzheimer’s disease by restoring brain insulin signaling. The findings bridge metabolic and neurodegenerative research, suggesting a broader therapeutic scope for SGLT2 inhibitors.
ICV CCK-8s Induces Anxiety-Like Behavior in Zebrafish: Mecha
2026-07-28
This study elucidates how intracerebroventricular (ICV) administration of two molecular forms of sulfated cholecystokinin octapeptide (CCK-8s) induces robust anxiety-like behavior in zebrafish, a model vertebrate. The findings clarify the neuroanatomical distribution of CCK-like peptides in the fish brain and highlight the conserved anxiogenic role of CCK signaling, informing assay design and translational neurobehavioral research.
Applied Workflows with Protease Inhibitor Cocktail (EDTA-Fre
2026-07-28
The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) by APExBIO empowers researchers to achieve uncompromised protein stability, even in demanding OXPHOS and kinase assay workflows. Explore protocol enhancements, troubleshooting, and evidence-driven tips for maximizing protein integrity in cell and tissue extracts.
MK 0893: Glucagon Receptor Antagonist for Type 2 Diabetes Re
2026-07-27
MK 0893 is a benchmark glucagon receptor antagonist enabling precise inhibition of GCGR for type 2 diabetes and metabolic research. Its robust performance in both cell-based and in vivo models supports advanced workflows, with reliable troubleshooting strategies for maximizing reproducibility and translational impact.
SM-102 in mRNA Delivery: Protocols and Innovations for LNPs
2026-07-27
SM-102 empowers researchers to efficiently encapsulate and deliver mRNA for advanced vaccine and therapeutic applications. Explore refined workflows, troubleshooting strategies, and data-backed insights that distinguish SM-102 as a pivotal lipid for robust mRNA delivery.
VE-821 ATR Kinase Inhibitor: Protocols, Use-Cases & Troubles
2026-07-26
VE-821 stands out as a selective ATR kinase inhibitor, enabling precise dissection of DNA repair pathways, radiosensitization, and combination chemotherapy strategies. This guide delivers actionable protocols, troubleshooting insights, and cross-domain perspectives to maximize experimental reliability in advanced DDR research.
TBXA2R-ERM Activation Drives TNBC Metastasis via GPCR Signal
2026-07-25
This study uncovers how the thromboxane A2 receptor (TBXA2R), a GPCR, activates ERM proteins to promote cell motility, invasion, and metastatic colonization in triple-negative breast cancer (TNBC). By delineating a TBXA2R–G protein–Rho GTPase–ERM axis, the research highlights new mechanistic insights and therapeutic targets for metastasis.
SP600125: Applied JNK Inhibitor Workflows and Troubleshootin
2026-07-24
SP600125 empowers researchers to dissect JNK-regulated pathways with unmatched selectivity, enabling robust apoptosis and inflammation assays in both cell culture and animal models. This guide translates mechanistic insight into actionable workflows, highlighting protocol optimization and troubleshooting strategies to maximize reproducibility and insight.
miR-196a Drives Esophageal Adenocarcinoma via MYC/TERT/NFκB
2026-07-24
This study elucidates how microRNA-196a enhances the aggressiveness of esophageal adenocarcinoma by orchestrating a MYC/TERT/NFκB signaling axis. The work identifies miR-196a as a driver of epithelial-to-mesenchymal transition and tumor progression, revealing actionable molecular targets for cancer research.
Stat3 Drives Fyn Kinase-Linked Dopaminergic Neurodegeneratio
2026-07-23
This paper establishes Stat3 signaling as a key downstream effector of Fyn kinase in mediating dopaminergic neuron loss and microglial activation in zebrafish. The findings clarify the molecular cascade underlying neurodegeneration and offer a precise in vivo model for interrogating Parkinson’s disease mechanisms and testing gene editing interventions.
460 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page